Carcinoma, Neuroendocrine - 25 Studies Found
Not yet recruiting |
: Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas : High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) : 2017-04-18 :
|
Not yet recruiting |
: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas : : 2024-05-13 |
Completed |
: KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors : Carcinoma, Neuroendocrine : 2014-08-21 : Drug: Selinexor Selective Inhibitor fo Nuclear Export (SINE) |
Recruiting |
: An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis : : 2024-05-13 |
Recruiting |
: A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours : : 2024-05-13 |
Completed |
: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma :
: 2005-06-07 :
|
Recruiting |
: SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma :
: 2015-07-06 : Drug: SC-002 SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks |
Recruiting |
: Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin : Neuroendocrine Carcinomas : 2016-02-18 : Drug: cisplatinum and everolimus Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 o |
Recruiting |
: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin : Neuroendocrine Carcinoma : 2016-02-17 : Drug: Everolimus Maintenance therapy Other Name: Afi |
Active, not recruiting |
: 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial : Neuroendocrine Carcinoma of the Lung and Thymus : 2012-03-20 :
|